


PHARMACEUTICAL 2022

Sage Therapeutics Inc. Rank 141 of 475







PHARMACEUTICAL 2022

Sage Therapeutics Inc. Rank 141 of 475



The relative strengths and weaknesses of Sage Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sage Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 228% points. The greatest weakness of Sage Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 3.8%, being 280% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	1,800,643
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	85,193
Liabilities, Non-Current	11,064
Other Assets	21,629
Other Compr. Net Income	-3,075
Other Expenses	553
Other Liabilities	0
Other Net Income	3,017
Property and Equipment	3,016
Research and Development	283,166
Revenues	6,308
Selling, General and Administrative Expense	183,498

Output Variable	Value in 1000 USD
Assets	1,825,288
Liabilities	96,257
Expenses	467,217
Stockholders Equity	1,729,031
Net Income	-457,892
Comprehensive Net Income	-459,430
Economic Capital Ratio	3.8%